title: Assessment of residual viability by enoximone echocardiography in patients with previous myocardial infarction correlation with positron emission tomographic studies and functional follow-up.
abstract: BACKGROUND
  The aim of this study was to evaluate enoximone echocardiography (EE) for the identification of residual myocardial viability in postinfarction patients. Findings obtained during EE were compared with those acquired by myocardial uptake of fluorine-18 fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and functional follow-up results.
  
  
  METHODS
  Twenty-five patients underwent EE and PET (18)F-FDG studies. An asynergic segment was considered as having contractile enhancement when the wall motion score decreased by > or = 1 grade during EE and was defined as viable if (18)F-FDG uptake score was > or = 2 grade on PET.
  
  
  RESULTS
  Of 293 dysfunctional segments at baseline, 139 (47%) were viable by PET criteria; 117 (40%) had contractile enhancement induced by enoximone (P = 0.07). Agreement between EE and PET was found in 75% of involved segments (K = 0.46, P < 0.001). The majority of discrepancies (65%, P < 0.01) were mainly due to discordant segments in which PET revealed evidence of (18)F-FDG uptake but EE showed no change in wall motion. In 179 revascularized segments, negative predictive value for functional recovery of both tests reached the same value (89% for both), whereas positive predictive value was 82% for EE and 68% for PET, respectively (P < 0.05). Sensitivity was 85% for EE and 88% for PET (P = ns); specificity was 87% and 70%, respectively (P < 0.01).
  
  
  CONCLUSIONS
  EE yields a fair concordance with PET study. Compared with PET, despite a similar negative accuracy, EE shows a greater specificity for prediction of function recovery after revascularization. (Echocardiography 2010;27:544-551).
authors.affiliation: Division of Cardiovascular Medicine, Cardiothoracic Department, University of Pisa, Pisa, Italy. Laolu@hotmail.it
authors.forename: Fei
authors.initials: F
authors.lastname: Lu
authors.forename: Mauro
authors.initials: M
authors.lastname: Carlino
authors.forename: Chunzeng
authors.initials: C
authors.lastname: Lu
authors.forename: Claudio
authors.initials: C
authors.lastname: Landoni
authors.forename: Giovanni
authors.initials: G
authors.lastname: Lucignani
authors.forename: Gabriele
authors.initials: G
authors.lastname: Fragasso
authors.forename: Vitantonio
authors.initials: V
authors.lastname: Di Bello
authors.forename: Alberto
authors.initials: A
authors.lastname: Margonato
authors.forename: Sergio L
authors.initials: SL
authors.lastname: Chierchia
authors.forename: Mario
authors.initials: M
authors.lastname: Marzilli
authors.forename: Alberto
authors.initials: A
authors.lastname: Balbarini
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D004452:Echocardiography / Q000379:methods*; D017335:Enoximone; D005260:Female; D019788:Fluorodeoxyglucose F18; D006439:Hemodynamics; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D009204:Myocardial Revascularization; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D014665:Vasodilator Agents
chemical_list: D019275:Radiopharmaceuticals; D014665:Vasodilator Agents; D019788:Fluorodeoxyglucose F18; D017335:Enoximone